Exscientia (EXAI) Stock Forecast, Price Target & Predictions
EXAI Stock Forecast
Exscientia stock forecast is as follows: an average price target of $5.00 (represents a 3.31% upside from EXAI’s last price of $4.84) and a rating consensus of 'Hold', based on 2 wall street analysts offering a 1-year stock forecast.
EXAI Price Target
The average price target for Exscientia (EXAI) is $5.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 3.31% upside from EXAI's last price of $4.84.
EXAI Analyst Ratings
According to 2 Wall Street analysts, Exscientia's rating consensus is 'Hold'. The analyst rating breakdown for EXAI stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 2 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Exscientia Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Peter Lawson | Barclays | $5.00 | $4.77 | 4.89% | 3.31% |
The latest Exscientia stock forecast, released on Aug 13, 2024 by Peter Lawson from Barclays, set a price target of $5.00, which represents a 4.89% increase from the stock price at the time of the forecast ($4.77), and a 3.31% increase from EXAI last price ($4.84).
Exscientia Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $5.00 |
| Last Closing Price | $4.84 | $4.84 | $4.84 |
| Upside/Downside | -100.00% | -100.00% | 3.31% |
In the current month, the average price target of Exscientia stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Exscientia's last price of $4.84. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 13, 2024 | Barclays | Overweight | Equal-Weight | Downgrade |
| Aug 08, 2024 | Cowen & Co. | Buy | Hold | Downgrade |
| Jul 09, 2024 | Cowen & Co. | - | Buy | Initialise |
| Nov 16, 2022 | Barclays | Overweight | Overweight | Hold |
Exscientia's last stock rating was published by Barclays on Aug 13, 2024. The company Downgrade its EXAI rating from "Overweight" to "Equal-Weight".
Exscientia Financial Forecast
Exscientia Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $5.76M | $8.20M | $7.03M | $8.66M | $9.16M | $4.14M | $17.64M |
| Avg Forecast | $26.17M | $24.67M | $12.59M | $8.07M | $13.24M | $4.48M | $6.62M | $7.23M | $6.11M | $21.09M | $39.01M | $24.47M | $7.50M | $13.17M |
| High Forecast | $26.17M | $60.92M | $12.59M | $8.07M | $13.24M | $4.54M | $6.62M | $7.23M | $6.11M | $21.09M | $39.01M | $24.47M | $7.50M | $13.17M |
| Low Forecast | $26.17M | $6.30M | $12.59M | $8.07M | $13.24M | $4.43M | $6.62M | $7.23M | $6.11M | $21.09M | $39.01M | $24.47M | $7.50M | $13.17M |
| # Analysts | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | 0.80% | 1.34% | 0.33% | 0.22% | 0.37% | 0.55% | 1.34% |
Exscientia's average Quarter revenue forecast for Jun 23 based on 1 analysts is $6.62M, with a low forecast of $6.62M, and a high forecast of $6.62M. EXAI's average Quarter revenue forecast represents a 14.94% increase compared to the company's last Quarter revenue of $5.76M (Mar 23).
Exscientia EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-38.18M | $-46.70M | $-49.72M | $-52.41M | $-34.94M | $-21.11M | $-5.51M |
| Avg Forecast | $-24.18M | $-22.80M | $-11.63M | $-7.46M | $-12.24M | $-4.15M | $-6.12M | $-6.68M | $-5.65M | $-19.95M | $-36.90M | $-23.14M | $-7.10M | $-12.45M |
| High Forecast | $-24.18M | $-5.82M | $-11.63M | $-7.46M | $-12.24M | $-4.10M | $-6.12M | $-6.68M | $-5.65M | $-19.95M | $-36.90M | $-23.14M | $-7.10M | $-12.45M |
| Low Forecast | $-24.18M | $-56.31M | $-11.63M | $-7.46M | $-12.24M | $-4.19M | $-6.12M | $-6.68M | $-5.65M | $-19.95M | $-36.90M | $-23.14M | $-7.10M | $-12.45M |
| Surprise % | - | - | - | - | - | - | - | 5.72% | 8.27% | 2.49% | 1.42% | 1.51% | 2.97% | 0.44% |
undefined analysts predict EXAI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Exscientia's previous annual EBITDA (undefined) of $NaN.
Exscientia Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $-37.64M | $-47.10M | $-39.62M | $-34.78M | $-20.35M | $-20.08M | $-5.08M |
| Avg Forecast | $-18.02M | $-25.95M | $-23.94M | $-37.79M | $-34.50M | $-42.02M | $-41.38M | $-42.12M | $-38.19M | $-33.51M | $-19.62M | $-16.89M | $-11.38M | $-15.42M |
| High Forecast | $-18.02M | $-25.95M | $-23.94M | $-37.79M | $-29.01M | $-42.02M | $-41.38M | $-42.12M | $-38.19M | $-33.51M | $-19.62M | $-16.89M | $-11.38M | $-15.42M |
| Low Forecast | $-18.02M | $-25.95M | $-23.94M | $-37.79M | $-39.98M | $-42.02M | $-41.38M | $-42.12M | $-38.19M | $-33.51M | $-19.62M | $-16.89M | $-11.38M | $-15.42M |
| Surprise % | - | - | - | - | - | - | - | 0.89% | 1.23% | 1.18% | 1.77% | 1.20% | 1.77% | 0.33% |
Exscientia's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. EXAI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Exscientia SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $10.91M | $9.90M | $11.51M | $14.63M | $10.27M | $6.38M | $8.60M |
| Avg Forecast | $31.67M | $29.85M | $15.23M | $9.77M | $16.03M | $5.43M | $8.01M | $8.74M | $7.39M | $25.03M | $46.31M | $29.04M | $8.91M | $15.63M |
| High Forecast | $31.67M | $73.73M | $15.23M | $9.77M | $16.03M | $5.49M | $8.01M | $8.74M | $7.39M | $25.03M | $46.31M | $29.04M | $8.91M | $15.63M |
| Low Forecast | $31.67M | $7.62M | $15.23M | $9.77M | $16.03M | $5.37M | $8.01M | $8.74M | $7.39M | $25.03M | $46.31M | $29.04M | $8.91M | $15.63M |
| Surprise % | - | - | - | - | - | - | - | 1.25% | 1.34% | 0.46% | 0.32% | 0.35% | 0.72% | 0.55% |
Exscientia's average Quarter SG&A projection for Jun 23 is $8.01M, based on 1 Wall Street analysts, with a range of $8.01M to $8.01M. The forecast indicates a -26.57% fall compared to EXAI last annual SG&A of $10.91M (Mar 23).
Exscientia EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $-0.31 | $-0.38 | $-0.32 | $-0.29 | $-0.17 | $-0.17 | $-0.04 |
| Avg Forecast | $-0.14 | $-0.20 | $-0.19 | $-0.30 | $-0.27 | $-0.33 | $-0.33 | $-0.33 | $-0.30 | $-0.26 | $-0.15 | $-0.13 | $-0.09 | $-0.12 |
| High Forecast | $-0.14 | $-0.20 | $-0.19 | $-0.30 | $-0.23 | $-0.33 | $-0.33 | $-0.33 | $-0.30 | $-0.26 | $-0.15 | $-0.13 | $-0.09 | $-0.12 |
| Low Forecast | $-0.14 | $-0.20 | $-0.19 | $-0.30 | $-0.32 | $-0.33 | $-0.33 | $-0.33 | $-0.30 | $-0.26 | $-0.15 | $-0.13 | $-0.09 | $-0.12 |
| Surprise % | - | - | - | - | - | - | - | 0.93% | 1.26% | 1.21% | 1.87% | 1.27% | 1.89% | 0.35% |
According to undefined Wall Street analysts, Exscientia's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to EXAI previous annual EPS of $NaN (undefined).
Exscientia Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| UBX | Unity Bio | $1.16 | $80.00 | 6796.55% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| IPSC | Century Therapeutics | $1.24 | $15.00 | 1109.68% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| ADAP | Adaptimmune Therapeutics | $0.64 | $2.83 | 342.19% | Buy |
| RLAY | Relay Therapeutics | $4.64 | $19.40 | 318.10% | Buy |
| PDSB | PDS Bio | $2.20 | $9.00 | 309.09% | Buy |
| ZURA | Zura Bio | $2.93 | $10.00 | 241.30% | Buy |
| SANA | Sana Bio | $2.35 | $8.00 | 240.43% | Buy |
| LPTX | Leap Therapeutics | $2.58 | $5.50 | 113.18% | Buy |
| AVIR | Atea Pharmaceuticals | $3.25 | $6.88 | 111.69% | Hold |
| MREO | Mereo BioPharma Group | $3.68 | $6.75 | 83.42% | Buy |
| RXRX | Recursion Pharmaceuticals | $5.75 | $9.67 | 68.17% | Hold |
| KYMR | Kymera Therapeutics | $43.51 | $51.50 | 18.36% | Buy |
| BPMC | Blueprint Medicines | $96.62 | $109.71 | 13.55% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $56.78 | $60.63 | 6.78% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| EXAI | Exscientia | $4.84 | $5.00 | 3.31% | Hold |